Is off-label prescribing illegal in the United States?

No. FDA explains that after a drug is approved, licensed clinicians generally may prescribe it for an unapproved use when they judge that use medically appropriate. That does not mean FDA reviewed safety and effectiveness for the new use. Off-label is still a prescription decision. It is not the same as buying an unapproved peptide or a supplement marketed to treat aging.

Are compounded longevity drugs the same as FDA-approved generics?

No. FDA states that compounded drugs are not FDA-approved, so the agency does not verify their safety, effectiveness, or quality before marketing. A generic is an approved copy of an approved drug. Compounding can help when an approved product cannot meet a documented need. It is not a routine way to create a cash-pay longevity stack.

What should I ask before starting a longevity drug or injection?

Ask the approved indication, whether your use is off-label, what evidence supports that use in someone like you, and how the clinic will monitor harm. Ask who is licensed to prescribe, what interactions will be checked, and when the plan stops. If the answer is a brand name without an indication, wait before you pay.

Does FDA approval mean a drug is safe for healthy aging?

No. Approval means FDA reviewed benefits and risks for a named use, not that the drug is risk-free or proven to extend life. A diabetes or transplant drug can still cause harm at a different dose or in a person without that diagnosis. Safety depends on indication, your history, other medicines, and follow-up—not the word approved alone.

FDA-Approved vs. Off-Label Longevity Therapies

What you are comparing

In U.S. longevity marketing, three different things get mixed together: a drug used for its FDA-approved indication, the same approved drug used off-label, and a product that is compounded or never approved. Those are not interchangeable. Approval applies to a specific use—condition, population, dose, and route—after FDA reviews evidence that benefits outweigh risks for that use.

Off-label use means a licensed clinician prescribes an approved drug for a different condition, dose, or group than the label. FDA states that clinicians generally may do this when they judge it medically appropriate. FDA has not determined that the drug is safe and effective for that unapproved use.

Compounded drugs sit in a third category. FDA says they are not FDA-approved, so the agency does not verify safety, effectiveness, or quality before they are marketed. Compounding can fill a real gap when an approved product cannot meet a medical need, such as an allergy to an inactive ingredient. It is not a general license to sell a longevity stack.

Unapproved injectables, research peptides, and dietary supplements marketed as anti-aging treatments are not off-label prescribing. Supplements are not approved to treat disease. The useful comparison is indication and evidence, not the word therapy on a clinic website.

How they differ

Evidence is the first split. An approved indication has a defined study population and a label that lists uses, dosing, and risks. Off-label use may rest on trials in a related disease, smaller studies, or clinical judgment. That evidence can be strong, mixed, or thin. You should hear which of those it is before you start.

Manufacturing and quality also differ. An approved drug is made under reviewed processes for that product. A compounded drug is prepared for an individual need and is not the same as a generic. FDA warns that unnecessary compounding can introduce quality problems. Products sold as research chemicals are not equivalent to a pharmacy prescription.

Cost and coverage follow the category. Insurance is more likely to pay for an approved indication than for an off-label longevity use. Compounded and cash-pay protocols are often billed as wellness. A higher price does not mean a stronger evidence base or a safer product.

Monitoring should change with uncertainty. Off-label use of a metabolic or hormone drug still needs labs, interaction review, and a stop rule. A clinic that cannot name the indication, the evidence, and the monitoring plan is selling a category, not a prescription decision.

Who each option is for

An approved use is the default when it matches your diagnosis. Examples include glucose-lowering drugs for diabetes, statins for indicated cardiovascular risk, and menopausal hormone therapy when a clinician judges benefits and risks for that person. Those are treatments for named conditions, not proof that the same drug extends life in healthy adults.

Off-label prescribing may be reasonable when approved options are exhausted or unavailable, the clinician names the evidence, and you accept uncertainty. It is a poor fit when the pitch is that everyone over 40 should take a diabetes or transplant drug for longevity without a diagnosis, baseline labs, or follow-up.

Compounding may fit when you cannot use an approved product because of a documented allergy, a needed dose form, or a shortage, and a licensed pharmacist or physician compounds for that need. It is not a fit when the clinic’s first plan is a custom peptide blend that copies an available approved drug.

None of these options is first-line for chest pain, unexplained weight loss, neurologic change, suicidal thoughts, or pregnancy complications. Those need urgent or conventional evaluation. People on anticoagulants, insulin, chemotherapy, or transplant drugs need interaction review before any add-on product.

Risks of choosing the wrong one

The main error is treating a website claim as an indication. You may receive a drug, injection, or supplement that was never reviewed for aging, while delaying care that has a clearer benefit, such as blood-pressure treatment, smoking cessation, or cancer screening. Time spent on an unapproved stack is still clinical time.

Off-label use without monitoring can cause predictable harm: hypoglycemia, blood-pressure change, clotting risk, mood change, or liver injury, depending on the agent. Safe because it is FDA-approved is incomplete. Approval is for a use. Your dose, combination, and health history change the risk.

Compounded and unapproved products add quality risk. FDA has documented contamination, potency errors, and illegal marketing of unapproved biologics. Buying peptides labeled not for human use from a website is not clinical care. Infection, wrong identity, and financial loss are documented problems, not rare footnotes.

Marketing language can hide conflicts. If the same visit sells the product, the lab panel, and the membership, ask whether the recommendation would stand if you filled a standard prescription elsewhere. FTC expects health claims to be truthful and scientifically supported. A clinic should separate evidence from inventory.

How to decide

Ask three questions before you start: What is the FDA-approved indication, if any? If this is off-label, what evidence supports this use in someone like me? How will we monitor harm and decide to stop? Write the answers down. Vague language about optimization is not an indication.

Prefer a licensed physician, nurse practitioner, or physician assistant who will document the diagnosis, review interactions, and share records with your primary care clinician. If the product is compounded, ask why an approved product cannot meet the need and who is accountable for quality.

Price the first 90 days: visit, labs, drug or compound, and follow-up. Set a stop rule, such as no change in a predefined measure or an adverse effect. Do not add a second unapproved product to interpret the first one.

Keep established prevention in place. USPSTF-recommended screening, vaccines, and risk-factor treatment still matter. A longevity protocol that replaces those is the wrong protocol. If symptoms are new or severe, get conventional evaluation first rather than another cash-pay add-on.

FDA-Approved vs. Off-Label Longevity Therapies

What you are comparing

How they differ

Who each option is for

Risks of choosing the wrong one

How to decide

Frequently Asked Questions

References

Guides

For Providers

Company